Orasure Technologies Inc. OSUR
Medical/Dental Instruments · data as of November 13, 2026
Orasure Technologies Inc. (OSUR) is a healthcare company listed in the US with a market value of about $250M. In the twelve months to September 30, 2026 it had revenue of $116M and net income of -$49M, a net margin of -41.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -8% a year, a 5-year average ROIC of -4%.
About Orasure Technologies
Orasure Technologies is listed in the US and classified in medical/dental instruments. Revenue went from $106M in 2014 to $115M in 2025, growth of about 0.7% a year. It was profitable in 5 of the last 10 years in our data. It spends 37% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116M | $115M | $186M | $405M | $387M | $234M | $172M | $155M | $182M | $167M | $128M |
| Net income | -$49M | -$69M | -$20M | $54M | -$17M | -$23M | -$15M | $17M | $20M | $31M | $20M |
| Free cash flow | -$50M | -$53M | $24M | $136M | -$54M | -$57M | -$21M | $490000 | $33M | $24M | $20M |
| EPS (diluted) | $-0.69 | $-0.94 | $-0.26 | $0.72 | $-0.24 | $-0.32 | $0.22 | $0.27 | $0.33 | $0.51 | $0.35 |
| Net margin | -41.7% | -59.8% | -10.5% | 13.2% | -4.4% | -9.8% | -8.7% | 10.8% | 11.2% | 18.5% | 15.4% |
| ROIC | — | -16.1% | -5.2% | 7.0% | -4.7% | -2.1% | -1.0% | 4.7% | 6.5% | 11.8% | 10.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $5.50, 52% above the current price; targets range from $4.00 to $7.00; the consensus rating is “Buy”; expected EPS is $-0.74 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Orasure Technologies pay a dividend?
Not currently.
Is Orasure Technologies a good stock to buy?
We do not give buy or sell advice. Orasure Technologies scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.